ESF1: A Potential Drug Target and Biomarker (G51575)

Target Name: ESF1

NCBI ID: G51575

ESF1

ESF1: A Potential Drug Target and Biomarker

ESF1 (ESF1 nucleolar pre-rRNA processing protein homolog) is a protein that is expressed in almost all eukaryotic cells and is involved in the formation and function of ribosomes. Its full-length coding gene consists of 111 nucleotides and is a protein of 198 amino acids in length. ESF1 plays an important biological role in cells and is part of the ribosome substructure. It is responsible for processing rRNA precursor molecules and converting them into mature rRNA, thereby participating in the protein synthesis process.

In recent years, ESF1 has received increasing attention as a drug target and biomarker. ESF1 has potential application value in the treatment of cancer, neurodegenerative diseases, liver diseases, immune system disorders and other diseases.

ESF1 in cancer treatment

ESF1 is widely used in the treatment of various cancers, such as liver cancer, breast cancer, gastric cancer, etc. Studies have shown that the expression level of ESF1 is positively correlated with tumor invasion and metastasis. In addition, the expression level of ESF1 is also related to the survival rate of tumor patients. Therefore, ESF1 has become a potential tumor therapeutic target.

ESF1 in neurodegenerative diseases

Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease are closely related to protein misfolding modifications and neuronal death. ESF1 plays an important role in neurons and can regulate neuron morphology, growth and apoptosis. Studies have found that the activity and expression levels of ESF1 are positively correlated with the progression of neurodegenerative diseases and the degree of neuronal damage. Therefore, ESF1 can become a new therapeutic target for neurodegenerative diseases.

ESF1 in liver disease

Liver disease is a common disease and is closely related to the expression level of ESF1. Studies have shown that the expression level of ESF1 is related to the severity and prognosis of liver disease. In addition, ESF1 is also closely related to liver cell apoptosis and liver cirrhosis. Therefore, ESF1 can become a new therapeutic target for liver diseases.

ESF1 in immune system disorders

Diseases caused by immune system disorders, such as autoimmune diseases, inflammatory bowel disease, etc., are closely related to the expression level of ESF1. Studies have shown that the expression level of ESF1 is related to the degree and severity of immune system disorders. Therefore, ESF1 can become a new therapeutic target for immune system disorders.

Structure and function of ESF1

ESF1 binds to ribosome substructures in the nucleus and ribosomes in the cytoplasm, participating in the protein synthesis process. ESF1 can form dimers, and each subunit consists of 49-52 amino acids. The active center of ESF1 contains an N-terminal 伪-helix, a central 尾-sheet, and a C-terminal domain.

ESF1 interaction

ESF1 can interact with other proteins, such as histones, H2A.L1, H2A.L2, etc. These interactions enable ESF1 to bind rRNA in ribosomes and participate in the protein synthesis process.

Clinical applications of ESF1

ESF1 has potential application value in multiple diseases. For example, ESF1 can be used as a target for the treatment of liver cancer, breast cancer, gastric cancer and other cancers. In addition, ESF1 can also be used as a therapeutic target for neurodegenerative diseases, liver diseases, immune system disorders and other diseases. Future research can further explore the role of ESF1 in clinical applications and explore the potential of ESF1 in disease treatment.

Protein Name: ESF1 Nucleolar Pre-rRNA Processing Protein Homolog

Functions: May constitute a novel regulatory system for basal transcription. Negatively regulates ABT1 (By similarity)

The "ESF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ESF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets